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http://www.malariajournal.com/content/12/1/399RESEARCH Open AccessAtovaquone-proguanil in the treatment of
imported uncomplicated Plasmodium falciparum
malaria: a prospective observational study of 553
cases
Hugues Cordel1,2, Johann Cailhol1,2, Sophie Matheron3, Martine Bloch4, Nadine Godineau5, Paul-Henri Consigny6,
Hélène Gros7, Pauline Campa8, Patrice Bourée9, Olivier Fain10, Pascal Ralaimazava1 and Olivier Bouchaud1,2*Abstract
Background: Each year, thousands of cases of uncomplicated malaria are imported into Europe by travellers.
Atovaquone-proguanil (AP) has been one of the first-line regimens used in France for uncomplicated malaria for
almost ten years. While AP’s efficacy and tolerance were evaluated in several trials, its use in “real life” conditions
has never been described. This study aimed to describe outcome and tolerance after AP treatment in a large cohort
of travellers returning from endemic areas.
Methods: Between September 2002 and January 2007, uncomplicated malaria treated in nine French travel clinics with AP
were followed for 30 days after AP initiation. Clinical and biological data were collected at admission and during the follow-up.
Results: A total of 553 patients were included. Eighty-eight percent of them were born in Africa, and 61.8% were infected in
West Africa, whereas 0.5% were infected in Asia. Migrants visiting friends and relatives (VFR) constituted 77.9% of the patients,
the remainder (32.1%) were backpackers. Three-hundred and sixty-four patients (66%) fulfilled follow-up at day 7 and 265
(48%) completed the study at day 30. Three patients had treatment failure. One-hundred and seventy-seven adverse drug
reactions (ADR) were reported during the follow-up; 115 (77%) of them were digestive ADR. Backpackers were more likely to
experiment digestive ADR compared to VFR (OR= 3.8; CI 95% [1.8-8.2]). Twenty patients had to be switched to another
regimen due to ADR.
Conclusion: This study seems to be the largest in terms of number of imported uncomplicated malaria cases treated by AP.
The high rate of reported digestive ADR is striking and should be taken into account in the follow-up of patients since it could
affect their adherence to the treatment. Beside AP, artemisinin combination therapy (ACT) is now recommended as first-line
regimen. A comparison of AP and ACT, in terms of efficacy and tolerance, would be useful.
Keywords: Atovaquone-proguanil, Imported, Uncomplicated, Malaria, ToleranceBackground
In 2010, the World Health Organization (WHO) esti-
mated that 216 million cases of malaria occurred and were
responsible of 650,000 deaths [1]. More and more people
travel from northern countries to malaria-endemic areas.
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reproduction in any medium, provided the orwhere approximately 7,000 cases were notified in 2010 to
the WHO Regional Office for Europe [2]. The actual case
numbers might be higher, due to under-notification. With
its historical links with West and Central Africa, France is
the leading European country in terms of cases of malaria
diagnosed with 3,560 cases reported in 2011 by the
National Malaria Reference Centre [3]. In Europe and other
northern countries, travellers are treated by highly effective
anti-malarial therapy, by contrast to malaria-endemic coun-
tries where appropriate treatments are not always available.
A recent publication has shown that 18 different regimensLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fixed combination, atovaquone-proguanil (AP), commer-
cially known as Malarone® [4].
AP has been licensed in France since 1997 and marketed
since late 2001 and it remains the principal treatment of
acute malaria. Since the National Experts Committee rec-
ommended in 2007 that AP, together with artemether-
lumefantrine, be used as first-line regimen, ‘old drugs’ such
as quinine or mefloquine were downgraded to second-line
treatment [5]. Atovaquone belongs to the family of
hydroxy-naphthoquinones, which anti-malarial activity
was first described 40 years ago [6,7]. Its mode of action is
original, blocking the electron transport chain of the para-
site’s mitochondria [8]. Used on its own, atovaquone has
limited value, as shown by a significant relapse rate [9]. Its
association with proguanil has shown excellent efficacy on
acute malaria in numerous clinical trials, due to a syner-
gistic effect [10-17]. AP is also widely used as an efficient
and well-tolerated chemoprophylaxis for travellers.
Efficacy and tolerance of AP were extensively reported
from clinical trials performed in malaria-endemic areas
[10-14]. However, these results might not be valid in the
case of imported malaria, due to epidemiological and
biological differences (i e, study conditions, immune sta-
tus, parasitaemia, heterogeneity of parasite strains, per-
ception of side effects). Most of the studies comparing
AP to other drugs were performed in endemic countries,
and few observational or retrospective studies from non
endemic countries have been published, amongst which
only was a comparative trial, yet with a limited number
of subjects has been published [18-24]. A recent inter-
national, prospective, observational study analysed a
large cohort (504 cases) of imported Plasmodium falcip-
arum malaria cases. It provided interesting data on the
use of AP with a relatively large series (n = 253), but
heterogeneity of practices, due to ‘centre effects’ between
participating European centres may limit the interpret-
ation of the study [4].
The aim of this study was to bridge this gap in know-
ledge by providing data on the use of AP in ‘real life’
conditions in France, using a large series of uncompli-
cated imported cases of P. falciparum.Methods
Study design
A multicentre, prospective, observational study was set
up in nine travel clinics located in Paris and its suburbs,
between September 2002 and January 2007. Written
informed consent was obtained from each participating
subject (from accompanying parents for children less
than 18 years old) and data management procedures
were approved by the French Commission National de
l’Informatique et des Libertés (CNIL).Study population
Recruitment criteria were as following: more than
12 years old (minimal age for prescribing the standard
dosage of AP according to manufacturer recommenda-
tions); an acute malaria onset due to P. falciparum,
acquired in an endemic country and imported to France;
onset treated with AP; and, having signed an informed
consent. Mixed infections, defined by an infection to
P. falciparum combined with another species of Plasmo-
dium were also included. Diagnosis of malaria was based
on positive Giemsa-stained thin and thick blood smears
tests performed by the parasitology laboratory in each
participating centre. All patients had to tolerate oral
therapy when they were included in the study. Patients
were excluded if: they fulfilled any of the clinical and
biological WHO criteria of severe or complicated mal-
aria [25], particularly parasitaemia higher than 4% even
for immune patients; if they had a history of allergy to
AP; if pregnant or breast-feeding. Hospitalization of pa-
tients was not required if the clinical status was suffi-
ciently good and if compliance to the treatment and
follow-up was foreseen as acceptable. Patients initially
treated with less than three days of intravenous quinine
because of vomiting at admission were not excluded as
tolerance data in that particular situation were of inter-
est. Decision for choosing AP or another anti-malarial
drug was the responsibility of each investigator. Data
were collected via a standardized datasheet and analysed
only for patients treated with AP.
Procedures/data collection
Initial evaluation included individual characteristics
(date of birth, sex, country of birth, country of resi-
dence), details on travels in malaria-endemic areas (date
of arrival in France, countries visited and duration of
travels), type of malaria prophylaxis, medical history
(co-morbidities and previous malaria onsets) and details
on actual onset. A semi-immune person was defined as
a patient who declared a history of malaria. Clinical
examination was followed by: blood smear; laboratory
test exploring liver, kidney, haematological and metabol-
ism functions; and, an electrocardiogram. According to
international and French follow-up guidelines, patients
were monitored at day 3, day 7 and one month (day 28
to 30) after AP initiation with clinical examination,
blood smear and haematological, liver and kidney func-
tions. Doses for AP and all anti-malarial drugs, except
mefloquine, is one tablet daily for chemoprophylaxis.
Compliance to daily chemoprophylaxis during the travel
period was evaluated during the initial interview: a good
compliance was defined by one or less missed dose by
week during the travel period and one month after
return. For mefloquine (MQ), compliance was defined
by one or less missed dose during the travel period and
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prophylaxis was defined as patients regularly using im-
pregnated bed net and skin repellent.
Apyrexia (fever clearance) was defined as a tympanic
temperature below 37.8°C and was monitored at day 3,
day 7 and one month. Parasite clearance was defined as
a negative thin/thick blood film and was monitored at
day 3, day 7 and one month.
Adverse drug reactions (ADR) were reported using a
questionnaire administered by the physician. An assess-
ment of patients’ perception of tolerance was performed,
using the following terms: good, satisfactory, bad, and
very bad tolerance. In the same way, assessment of pa-
tients’ perception of AP efficacy was performed. Patients
were asked their subjective feeling about the treatment,
using the following items: efficient, moderately, poorly
and not efficient in the questionnaire, without clinical or
biological data. Data were captured on a standardized
datasheet and transmitted to the study principal investi-
gator at the end of follow-up. A limited number of pa-
tients were also included in another observational study
(the European Malther study) recently published [4].
Data analysis
Statistical analysis was performed using Stata® version 10
software (StataCorp LP, 4905 Lakeway Drive, College
Station, TX 77845, USA). Descriptive analyses were
comprised of frequency distributions and proportions
for each variable category, with their quartiles and confi-
dence intervals (CI) 95%. Group comparisons were per-
formed using Chi square test and Fisher’s exact test for
categorical variables. Spearman's rank correlation co-
efficient was used to assess association between two
continuous variables. Logistic regression analysis was
performed to measure association between digestive
ADR and patient’s characteristics as independent vari-
ables: sex, age group, country of birth, chronic illness
(cardiopathy, obesity, diabetes mellitus, kidney and re-
spiratory diseases, HIV infection), type of chemoprophy-
laxis, type of travel, parasitaemia at diagnosis and at day
3 nausea at presentation, defined as nausea reported
at diagnosis, and immunity, classified in semi-immune
person or non immune”.
Odds ratios (OR) and 95% CI were calculated from
β coefficients and their standard errors. Variables with a
p-value < 0.30 were included in the adjusted model.
Results
Population
During the study period, 553 patients met eligibility cri-
teria and were enrolled in the study. The median age of
patients was 38.3 years old (12–79) and 66% were male
(sex ratio 1.9). The majority of patients (90.8%) were born
outside Europe, mainly in Africa (88.6%). Information onco-morbidities was available for 478 (86.4%): 21 were HIV
positive (4%); and 44 (7.9%) had a cardiopathy. Nearly half
of enrolled patients (n = 264; 47.7%) declared at least one
previous onset of malaria.
Countries of contamination were mainly located in
Africa, especially West Africa for 342 (61.8%) travellers.
Only three (0.5%) and two (0.4%) were infected in Asia
and the Caribbean Islands, respectively. Most of the pa-
tients were migrants who visited friends and relatives
(VFR) (n = 431, 77.9%). Others were backpackers (n = 33,
6.0%) and tourists resident in hostels (n = 11, 2.2%).
A pre-travel consultation was reported in 267 travel-
lers (48.3%), mostly by their family practitioner (42.3%).
Two-hundred and twenty-two patients (40.1%) declared
having taken malaria chemoprophylaxis (chloroquine-
proguanil in 64% of the cases). Information on compli-
ance to chemoprophylaxis was available for 222 subjects
and was classified as good for 50 cases (22.5%). Seventy-
eight subjects (14.1%) declared having used exposure
prophylaxis, including 12 (2.2%) with appropriate expos-
ure prophylaxis, i e, regular use of impregnated bed net
and skin repellent. Twenty patients (3.6%) experienced
digestive disorders during their stay. There was no rela-
tionship between malaria chemoprophylaxis and digest-
ive disorders (p = 0.14). Twenty-two patients were
treated by intravenous quinine (14 patients for 24 hours
or less, four for 48 hours and four for 72 hours) before
receiving AP because of vomiting at admission. Table 1
summarizes the main characteristics of patients enrolled.
Diagnosis
The median time between onset and diagnosis was five
days [1–64]. Initial clinical presentation comprised head-
ache (46.3%), nausea and vomiting (28.2%), diarrhoea
(18.5%), myalgia (14.7%), abdominal pain (5.8%) and
arthralgia (3.6%). For 175 patients (31.6%), no fever was
noted at admission (Table 2).
Biology
The main data are summarized in Table 3. All patients
were infected by P. falciparum. In two cases P. falciparum
was associated with another species: one with Plasmodium
vivax from India and one with Plasmodium ovale from
Gabon.
Median parasitaemia at diagnosis was 0.52% of red
blood cell (0.01-5.0). Haemoglobin level was under or
equal 8 g/dL at day 3 for 18 patients (3.9%) compared to
ten (1.9%) at diagnosis (p < 10-3). There was no correlation
between parasitaemia and haemoglobin level at diagnosis
(r = −0.0017, p = 0.97). There was no correlation between
the time elapsed between symptoms onset and diagnosis
on one hand and haemoglobin level at diagnosis or at day
3 on the other hand (r = −0.21, p < 10-3 and r = −0.22,
p < 10-3, respectively). At admission, platelets count was
Table 1 Main characteristics of 553 patients treated
with atovaquone-proguanil for imported uncomplicated
malaria
Male: female ratio 1.9
Median age in years 38.3 (12–79)
Median weight (kg) 74 (40–109)
Continent of birth N (%)
Europe 51 (9.2)
French West Indies 4 (0.7)
Africa 490 (88.6)
Others 8 (1.5)
Previous history of malaria 264/492* (53.7)
HIV positive 21/478* (4.4)
Pre-travel visit 267 (48.3)
Travel clinic 74 (27.7)
Family doctor 113 (42.3)
Unknown 80 (30.0)
Chemoprophylaxis 222 (40.1)
Chloroquine 30 (13.5)
Chloroquine-proguanil 142 (64)
Mefloquine 24 (10.8)
Atovaquone-proguanil 1 (0.4)
Doxycycline 13 (5.9)
Proguanil 10 (4.5)
Unknown 2 (0.9)
Compliance to chemoprophylaxis 50/222* (22.5)
Non-medical prophylaxis
Air-conditionning only 1 (0.2)
Insecticides only 5 (0.9)
Unimpregnated bed net only 11 (2)
Impregnated bed net only 23 (4.1)
Repellents only 23 (4.1)
Impregnated bed net and repellents 12 (2.2)
No prophylaxis 400 (72.4)
Unknown 78 (14.1)
Place of contamination
West Africa 342 (61.8)
Central Africa 148 (26.8)
Madagascar and Comoros 51 (9.2)
East Africa 5 (0.9)
Asia 3 (0.5)
Angola and South Africa 2 (0.4)
Haïti and French Guyana 2 (0.4)
Table 1 Main characteristics of 553 patients treated
with atovaquone-proguanil for imported uncomplicated
malaria (Continued)
Type of travel
Backpackers 33 (6.0)
Hostel 11 (2.0)
Visiting friends and relatives 431 (77.9)
Unknown 78 (14.1)
*: number of patients with available data.
Table 2 Admission variables and outcome in 553 patients
treated with atovaquone-proguanil for imported uncom-
plicated malaria
Temperature at diagnosis N (%)
≤37.7C° 175 (31.6)
37.8-39C° 208 (37.6)
39.1-40C° 104 (18.8)
>40C° 19 (3.4)
Symptoms at diagnosis
Headache 256 (46.3)
Nausea/vomiting 156 (28.2)
Diarrhoea 102 (18.5)
Myalgia 81 (14.7)
Abdominal pain 32 (5.8)
Arthralgia 20 (3.6)
Compliance to follow-up
Day 3 469 (84.1)
Day 7 364 (65.8)
Day 30 265 (47.9)
Hospitalization
Hospitalized at diagnosis 191 (34.5)
Still hospitalized at day 3 124 (22.4)
Still hospitalized at day 7 15 (2.7)
Still hospitalized at day 30 2 (0.3)
Fever clearance (apyrexia)
Day 3 403/425* (94.8)
Day 7 323/323* (100)
Day 30 227/227* (100)
Parasitological clearance (negative parasitaemia)
Day 3 292/425* (68.7)
Day 7 331/331* (100)
Day 30 215/217* (99.1)
*: number of patients with available data.
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Table 3 Biology data in 553 patients treated with atovaquone-proguanil for imported uncomplicated malaria
Diagnosis Day 3 Day 7 Day 30
Haemoglobin (g/dL) N (%) N (%) N (%) N (%)
≤8 11 (1.9) 16 (3.4) 4 (1.1) 0
8.1-10 28 (5.1) 55 (11,7) 48 (13.2) 17 (6.4)
10.1-12 136 (24.6) 162 (34.6) 126 (34.6) 73 (27.6)
>12 378 (68.4) 236 (50.3) 186 (51,1) 175 (66.0)
Platelets count (per mm3)
≤20,000 8 (1.4) 4 (0.8) 0 0
20,001-50,000 43 (7.8) 14 (3.0) 1 (0.3) 0
50,001-100,000 173(31.3) 102 (21.8) 1 (0.3) 0
100,001-150,000 160 (28.9) 121 (25.8) 6 (1.6) 7 (2,6)
>150,000 169 (30.6) 228 (48.6) 356 (97.8) 258 (97,4)
Leucocytosis
White blood cells ≤4,500 per mm3 218 (39.4) 242 (51.6) 55 (15.1) 48 (18.1)
White blood cells >4,500 per mm3 335 (60.6) 227 (48.4) 309 (84.9) 217 (81.9)
Cytolysis
ALAT ≤1 N 385 (69.6) 287 (61.2) 201 (55.2) 219 (82.6)
ALAT 1.1-2 N 135 (24.4) 140 (29.9) 117 (32.1) 44 (16.6)
ALAT 2.1-3 N 27 (4.9) 24 (5.1) 20 (5.5) 2 (0.8)
ALAT >3 N 6 (1.1) 18 (3.8) 26 (7.1) 0
Creatinine (μmol/L)
≤120 507 (91.7) 431 (91.9) 349 (95.9) 4 (1.5)
121-140 36 (6.5) 25 (5.3) 8 (2.2) 253 (95.5)
>140 10 (1.8) 13 (2.8) 7 (1.9) 8 (3.0)
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20,000/mm3 in eight patients (1.5%). At day 7, 99.4% of
patients had more than 100,000 platelets/mm3.
Outcome
Follow-up was the following: 469 patients (85%) at day
3, 364 at day 7 (66%) and 265 patients (48%) completed
the study one month after diagnosis. About one third of
patients were hospitalized (n = 191, 34.5%). At day 3, 124
(22.4%) were still hospitalized and 15 (2.7%) at day 7. At
one month, two patients were hospitalized: the first one
was re-hospitalized for a relapse; the second one defin-
itely cleared his parasitaemia at day 3 but was still hospi-
talized at day 30 for an HIV-related complication.
Fever clearance was obtained at day 3 in 95% of cases
(403 of 425 for which information were available) and
for all patients at day 7 (Table 2). All patients at one
month were apyretic. Negative parasitaemia was ob-
served in 68.7% of patients at day 3 and for all patients
at day 7. Treatment failure was observed in three pa-
tients: two relapsed at day 30 and one at day 23. During
follow up, these three patients did not return to an
endemic area. All were successfully treated by meflo-
quine. Perceived efficacy amongst the 419 patients whoanswered was classified as efficient for 305 (72.8%),
moderately for 101 (24.1%), poor for eight (1.9%) and
not efficient for five (1.2%).Adverse drug reactions and drug switch
A total of 177 adverse drug reactions (ADR) attributed to
AP were reported by the patients during the follow-up.
Most of them were reported at day 3 (n = 150) and were
digestive (n = 115, 77% of all ADR reported at day 3): most
of them consisted of nausea and vomiting followed by
headache and skin disorders (Table 4).
In the multivariate analysis, when adjusted to origin,
type of travel and parasitaemia at diagnosis, backpackers
were more likely to experiment digestive ADR at day 3
than VFR (OR = 3.8 CI 95% [1.8-8.2]) (Table 5).
Assessment of tolerance by patients for the 437 who an-
swered to the questionnaire was classified as good for 304
(69.6%), satisfactory for 116 (23.8%), bad for 41 (8.4%) and
very bad for 27 (5.5%). In 20 cases, a switch to another
drug was reported mainly because of vomiting (n = 15,
75%), confusion (n = 2, 10%), headache (n = 1, 5%), cutane-
ous eruption (n = 1, 5%), and suspected resistance because
of a positive smear at day 3 (n = 1, 5%).
Table 4 Main adverse drug reactions in 553 patients
treated with atovaquone-proguanil for imported uncom-
plicated malaria
At Day 3 (N = 469 (%)) n (%)
Digestive adverse reactions 115 (24.5)
Nausea or vomiting 82 (17.5)
Diarrhoea 16 (3.4)
Abdominal pain 10 (2.1)
Others 7 (1.5)
Cutaneous 10 (2.1)
Headache 18 (7.4)
Myalgia 3 (0.6)
Arthralgia 3 (0.6)
Anxiety 1 (0.2)
Total ADR° at Day 3 150 (32.0)
At Day 7 (N = 364 (%))*
Digestive adverse reactions 11 (3.0)
Nausea 3 (0.8)
Diarrhoea 4 (1.1)
Others 4 (1.1)
Cutaneous 7 (1.9)
Headache 7 (1.9)
Total ADR° at Day 7 25 (6.9)
At Day 30 (N = 265 (%))*
Digestive adverse reactions 1 (0.4)
Nausea 0
Diarrhoea 1 (0.4)
Cutaneous 1 (0.4)
Headache 0
Total ADR* at Day 30° 2(0.8)
*: Differences between denominators are due to patients lost to follow up.
ADR: Adverse drugs reactions.
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This ‘real life condition’ prospective, observational study of
553 patients treated by AP for uncomplicated P. falciparum
malaria seems to be the largest series assessing the use of
AP in the field of imported malaria. Patient profile (mostly
young male adults of African origin living in Europe and in-
fected in West Africa) are similar to those observed in the
majority of studies on imported malaria [18-24,26-28]. The
high percentage of HIV-infected patients (4.4%) observed
in the study may be explained by the fact that the majority
of patients are of African origin and because the nine
recruiting centres are travel clinics linked to infectious dis-
eases departments where a majority of the HIV patients
living in Paris area are followed.
Not surprisingly, the rate of chemoprophylaxis and
exposure prophylaxis was low. Clinical and biological
presentation had no specificity but it is of interest tonote that nearly one third of patients had no fever at ad-
mission, which might be misleading for non-experienced
practitioners. Compared to some other studies describ-
ing non-comparative cohorts of malaria patients, follow-
up, even too low, might be considered satisfactory given
such a ‘real life’ design for this cohort, since outcome
data are available for the majority at day 3 and since
nearly half of patients were seen one month after treat-
ment [16,19-21,26-29]. By contrast the loss to follow-up
rate at one month in the recent European study was
much lower, at 25% [4].
With regard to efficacy, if a majority of patients (95%)
were fever-free at day 3, nearly a third of them were still
parasitaemic confirming that AP is slow-acting [15,16,19,
20,30,31]. The analysis of efficacy in a per-protocol ap-
proach gives a cure rate of 99% (three relapses of 265 pa-
tients with a follow-up at one month) which is comparable
to other treatments [15,16,22,32,33]. Details on relapses
were available for only two cases. In both cases the reason
was probably suboptimal plasmatic AP level: consecutive to
obesity (115 kg) in one case and to a poor absorption in the
second case, since the patient had not taken food with the
drug [34]. As a consequence, physicians should re-assess
AP dosage in obese patients and should insist on food in-
take with AP to optimize its absorption.
Even though rare under AP and comparable to other
malaria treatment (1% in this study’s series), the risk of
relapse has to be considered by physicians given the po-
tential severe outcome at a time when the diagnosis of
malaria may be omitted (long delay after travel in en-
demic area) [4,21,23]. Given that relapses occur usually
between day 14 and day 30 (and in a few cases later)
after treatment, physicians should organize a ‘recapture’
system for patients lost to follow-up after day 7, even
limited to a phone call, in order to identify promptly a
possible recrudescence [4,35].
Perceived efficacy of AP was satisfying. This evaluation
is not as valid as parasitological efficacy but it has not
been studied in Africa before, both for curative treat-
ment and for prophylaxis in travellers. It is considered as
a significant predictor for compliance to treatment and
preventative behaviours [36,37].
With regard to tolerance of AP, data of this study
highlighted a high rate of digestive ADR, mainly at day 3,
especially nausea and vomiting. Digestive ADR repre-
sented 77% of ADR reported at day 3 and 72% of the total-
ity of ADR reported during follow-up. It seems that
digestive ADR were more frequent in backpackers com-
pared to migrants, with no particular explanation, and no
comparable data were found in the literature. In 18% of
cases (n = 15), vomiting was severe enough to justify a
change to second-line treatment. This high occurrence of
digestive ADR could be partially explained by the popula-
tion enrolled in the study since black people are known to
Table 5 Digestive adverse drug reactions under atovaquone-proguanil
Number Digestive ADR day 3 Crude OR p Adjusted OR p
N (%)
Sex Male 306 74 (24.2) 1 0.82
Female 163 41 (25.1) 0.9 [0.6 - 1.4]
Age ≤ 30 131 39 (29.8) 1 0.36
31-40 129 27 (20.9) 0.6 [0.3 - 1.1]
41-50 121 30 (24.8) 0,8 [0.4 - 1.3]
> 50 88 19 (21.6) 0.6 [0.3 - 1.2]
Origin African 415 92 (22.2) 1 <0.01 1 0.19
European 43 16 (37.2) 2.1 [1.0 - 4.0] 1.2 [0.5 - 2.8]
Others 11 7 (63.6) 6.1 [1.7 - 21.4] 3.5 [0.9 - 14.0]
Immunity Non immune 233 60 (25.7) 1 0.54
Semi-immune 236 55 (23.3) 0.88 [06 – 1.3]
Nausea at presentation No 329 82 (24.9) 1 0.76
Yes 140 33 (23.6) 0.93 [0.58 – 1.48]
Chronic illness No 425 105 (24.7) 1 0.77
Yes 44 10 (22.7) 0,9 [0.4 - 1.9]
Chemoprohylaxis No 192 50 (26.0) 1 0.51
Yes 277 65 (23.5) 0.9 [0.6 - 1.3]
Type of travel VFR* 378 80 (21.2) 1 < 0.01 1 < 0.01
Hostel 10 4 (40.0) 2.5 [0.7 - 9.0] 2.8 [0.8 - 10.4]
Backpackers 30 15 (50.0) 3.7 [1.7 - 7.9] 3.8 [1.8 - 8.2]
Unknown 51 16 (31.4) 1.7 [0.9 - 3.2] 1.7 [0.9 - 3.9]
Parasitaemia at diagnosis ≤ 0.10% 144 27 (18.7) 1 0.29 1 0.26
0.11 - 0.50% 148 42 (28.4) 1.7 [1.0 - 3.0] 1.8 [1.0 - 3.1]
0.51 - 1.00% 52 11 (21.2) 1.2 [0.5 - 2.5] 1.3 [0.6 - 2.9]
> 1% 90 25 (22.8) 1.7 [0.9 - 3.1] 1.9 [1.0 - 3.5]
Unknown 35 10 (28.6) 1.7 [0.7 - 4.0] 1.8 [0.7 - 4.2]
Parasitaemia at day 3 Negative 290 72 (24.8) 1 0.97
Positive 128 31 (24.2) 0.9 [0.6 - 1.6]
Unknown 51 12 (23.5) 0.9 [0.5 - 1.9]
*Visiting friends and relatives.
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white people [38]. Yet there were no relationship between
immunity, or African origin, with digestive ADR.
Surprisingly, these digestive side effects are one of the
most important from studies. A review of ten trials compar-
ing Atovaquone-Proguanil (AP) with other anti-malarial
drugs for uncomplicated malaria report a median rate
of nausea and/or vomiting (inter quartile range) of 15.6%
(5.2 – 25.0) for Atovaquone-Proguanil whereas other stud-
ies did not report this ADR [10,11,15,16,18,20,30,31,39]. To
discriminate digestive ADR from symptoms related to mal-
aria is difficult in a cohort and only clinical trials would be
able to make the distinction. This study didn’t compare AP
to other drugs, and this misclassification could be a bias.Nausea at diagnosis was not associated with digestive ADR
at day 3, which involves AP rather than acute malaria in
the etiology of these adverse effects.
Nevertheless, data from this series on digestive ADR
are comparable to the results of a recent cohort study
showing a higher switch rate to second-line treatment in
patients treated with AP, compared to others [4].
The design of this study does not enable to guide phy-
sicians on their choice of anti-malarial drug. However,
the significant risk of vomiting associated with AP needs
to be taken into account, especially in patients already
complaining of nausea and vomiting at the time of diag-
nosis. The need for fat intake with AP, as is recom-
mended to improve absorption, may be an additional
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mide is probably not a solution since it decreases the
bioavailability of atovaquone [40].
As observed in the literature, this study did not reveal
any liver toxicity. Moderate variations in transaminase
level observed at day 3 and 7 were not significant and
were possibly due to malaria parasite itself [12,14,30,41].
A drop in haemoglobin level, as observed here, was
commonly reported after initiation of treatment of acute
malaria due to malaria haemolysis [42]. The absence of
correlation between haemoglobin at diagnosis and initial
parasitaemia is in line with other studies [43].
In 2007, French experts’ consensus recommended both
AP and artemether-lumefantrine as first-line treatment
for acute uncomplicated malaria [5]. As a consequence
and because artemether-lumefantrine, even if registered
throughout Europe in 1999, is only available since 2007
in France, the use of AP has progressively increased
from 25% in 2006 to 46% in 2011 [3]. On the one hand,
AP’s good efficacy was confirmed by this series while its
limitations were described (mainly slow-acting drug,
poor absorption, and ADR, such as vomiting). On the
other hand, use of artemether-lumefantrine in the par-
ticular situation of imported malaria still has a limited
experience. Hence, regarding imported malaria, the
question of which association between AP or artemisinin
combination therapy (ACT) is the best option remains.
A clinical trial is currently comparing the use of AP and
ACT in the indication of uncomplicated malaria in non-
endemic areas and will hopefully bring the answer [44].
With the introduction of ACT in Europe (artemether-
lumefantrine and, since mid-2012, dihydroartemisinin-
piperaquine are both authorized in France and in a limited
number of European countries) for uncomplicated acute
malaria onset, the use of AP will probably decrease
in favour of ACT, due to its prompt efficacy and good
tolerance.
Conclusion
This observational series of 553 cases, the largest to date
in number of patients, describes a large experience in
using AP for imported uncomplicated malaria in real life
conditions. Despite a non-comparative design, it appears
that its efficacy is good and comparable to other similar
drugs. The study confirms that AP is a valuable treatment
option, while ADR, such as vomiting and its limited
absorption in some cases, may be a limitation for its use.
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